Patents Assigned to Aventis Pharmaceuticals Products Inc.
-
Publication number: 20070101451Abstract: Lipoprotein Lipase like polypeptides, nucleic acids encoding said polypeptides, antisense sequences, and antibodies to said polypeptides are disclosed. Also disclosed are methods for the preparation of said polypeptides in a recombinant system and for the use of said polypeptides to screen for agonists and or antagonists of said polypeptides. Also disclosed are methods and compositions for the treatment of disorders of lipid metabolism.Type: ApplicationFiled: March 7, 2006Publication date: May 3, 2007Applicant: Aventis Pharmaceuticals Products Inc.Inventors: Michael Jaye, Kim-Anh Doan, John Krawiec, Kevin Lynch, Dilip Amin, Victoria South
-
Publication number: 20060223771Abstract: The present invention is directed to nuclear factor ?B (NF?B)-inducing factor polypeptides (NFIF polypeptides) which are capable of inducing NF?B. The present invention includes within its scope NFIF polypeptides, including NFIF-14b and NFIF-7a, DNA, including cDNA, encoding these polypeptides, and expression vectors capable of expressing NFIF polypeptides. Also included are methods and compositions for increasing NF?B induction in a patient, methods and compositions for lowering NF?B induction in a patient, methods for inhibiting inflammation, and methods for manufacutre of a medicament intended for the treatment and/or prevention of an NF?B-regulated inflammatory response. In addition, methods for determining whether a test compound inhibits or enhances the activity of NFIF polypeptides are provided.Type: ApplicationFiled: February 15, 2006Publication date: October 5, 2006Applicant: Aventis Pharmaceuticals Products Inc.Inventors: June Kaplow, Thomas Haws, Marie Rosier, Patrice Denefle
-
Patent number: 7041497Abstract: The present invention is directed to nuclear factor ?B (NF?B)-inducing factor polypeptides (NFIF polypeptides) which are capable of inducing NF?B. The present invention includes within its scope NFIF polypeptides, including NFIF-14b and NFIF-7a, DNA, including cDNA, encoding these polypeptides, and expression vectors capable of expressing NFIF polypeptides. Also included are methods and compositions for increasing NF?B induction in a patient, methods and compositions for lowering NF?B induction in a patient, methods for inhibiting inflammation, and methods for manufacture of a medicament intended for the treatment and/or prevention of an NF?B-regulated inflammatory response. In addition, methods for determining whether a test compound inhibits or enhances the activity of NFIF polypeptides are provided.Type: GrantFiled: March 30, 2001Date of Patent: May 9, 2006Assignee: Aventis Pharmaceuticals Products Inc.Inventors: June Kaplow, Thomas Haws, Marie Rosier, Patrice Denefle
-
Publication number: 20020146829Abstract: Processes for making neutral or anionic complexes containing sequestered DNA for gene transfer, by forming a stable colloid containing an aqueous phase having suspended therein a first DNA complex with a cationic surface potential comprising a DNA sequence complexed with a cationic lipid or polymer, and modifying the surface potential of the first DNA complex to form a stable colloid comprising a second DNA complex with a neutral or net anionic surface potential.Type: ApplicationFiled: November 29, 2001Publication date: October 10, 2002Applicant: Aventis Pharmaceuticals Products Inc.Inventors: Hans Hofland, Donald Lamons, Xiao-Ying Meng
-
Patent number: 6391980Abstract: Solid substrates and methods for their preparation are provided, where enhanced functionalization of solid substrates is achieved, so that higher levels of binding of a wide variety of moieties can be obtained. The surface is nitrated with a nitronium agent, where the nitro groups may be modified in a variety of ways to serve as sites for linking. The resulting solid substrates find use in therapy, diagnosis and processing.Type: GrantFiled: June 7, 1995Date of Patent: May 21, 2002Assignee: Aventis Pharmaceuticals Products, Inc.Inventor: Brian Clark
-
Patent number: 6361936Abstract: Solid substrates and methods for their preparation are provided, where enhanced functionalization of solid substrates is achieved, so that higher levels of binding of a wide variety of moieties can be obtained. The surface is nitrated with a nitronium agent, where the nitro groups may be modified in a variety of ways to serve as sites for linking. The resulting solid substrates find use in therapy, diagnosis and processing.Type: GrantFiled: May 8, 1995Date of Patent: March 26, 2002Assignee: Aventis Pharmaceuticals Products, Inc.Inventor: Brian Clark
-
Patent number: 6323227Abstract: This invention relates to compounds of formula which inhibit Factor Xa, to pharmaceutical compositions containing the compounds, and to the use of the compounds for the treatment of patients suffering from conditions which can be ameliorated by the administration of an inhibitor of Factor Xa.Type: GrantFiled: February 26, 1999Date of Patent: November 27, 2001Assignee: Aventis Pharmaceuticals Products Inc.Inventors: Scott I. Klein, Kevin R. Guertin, Alfred P. Spada, Heinz W. Pauls, Yong Gong, Daniel G. McGarry
-
Patent number: 6306873Abstract: This invention relates to compounds of general formula (I): in which Ar is a group selected from: A1, A2, B, C, D, E, Q1-Q3, R1-R9, Z1 and Z2 are as defined in the disclosure, and Y represents carboxy or an acid bioisostere. These compounds inhibit the production or physiological effects of TNF and inhibit cyclic AMP phosphodiesterase. The invention is also directed to pharmaceutical compositions comprising compounds of formula (I), their pharmaceutical use and methods for their preparation.Type: GrantFiled: July 20, 1999Date of Patent: October 23, 2001Assignee: Aventis Pharmaceuticals Products Inc.Inventors: Christopher J. Burns, Richard Labaudiniere, Stephen Condon, Robert D. Groneberg, Rose M. Mathew, Joseph M. Salvino
-
Patent number: 6307054Abstract: The present invention is directed to a process for preparing 2,4-dihydroxy-pyridine comprising heating a compound of the formula A wherein R is H, alkyl or aralkyl and phosphoric acid where the ratio of phosphoric acid to water is not less than about 27 to 1 weight %. The invention is also directed to a process for preparing 2,4-dihydroxy-3-nitropyridine comprising reacting 2,4-dihydroxypyridine with nitric acid. The processes of the present invention prepare intermediates which are useful in preparing compounds which are useful for treating cardiovascular disease marked by hypertension or myocardial ischemia, ameliorating ischenic injury or myocardial infarct size, or treating hyperlipidemia or hypercholesterolemia.Type: GrantFiled: July 1, 1998Date of Patent: October 23, 2001Assignee: Aventis Pharmaceuticals Products Inc.Inventors: Larry K. Truesdale, James P. Sherbine, Benoit J. Vanasse
-
Patent number: 6277865Abstract: This invention is directed to a compound of formula I which is useful for inhibiting the activity of Factor Xa, by combining said compound with a composition containing Factor Xa. The present invention is also directed to compositions containing compounds of the formula I, methods for their preparation, their use, such as in inhibiting the formation of thrombin or for treating a patient suffering from, or subject to, a disease state associated with a physiologically detrimental excess amount of thrombin.Type: GrantFiled: March 22, 1999Date of Patent: August 21, 2001Assignee: Aventis Pharmaceuticals Products Inc.Inventors: Scott I. Klein, Kevin R. Guertin
-
Patent number: 6274705Abstract: The present invention relates to azacycloalkylalkanoyl peptides and pseudopeptides which inhibit platelet aggregation and thrombus formation thereby being useful in the prevention and treatment of thrombosis associated with disease states such as myocardial infarction, stroke, peripheral arterial disease, and disseminated intravascular coagulation, to methods for the prevention or treatment of thrombosis in a mammal in need of such therapy comprising the administration of a therapeutically effective amount of such compounds, and to pharmaceutical compositions comprising such compounds.Type: GrantFiled: August 21, 1998Date of Patent: August 14, 2001Assignee: Aventis Pharmaceuticals Products Inc.Inventors: Scott I. Klein, Bruce F. Molino
-
Patent number: 6258596Abstract: The present invention relates to variants of the human apolipoproteine A-I comprising a cystein in position 151, the corresponding nucleic acids and the vectors containing them. It also relates to pharmaceutical compositions comprising said elements and their utilization, particularly in genic therapy.Type: GrantFiled: June 5, 1998Date of Patent: July 10, 2001Assignee: Aventis Pharmaceuticals Products Inc.Inventors: Patrick Benoit, Eric Bruckert, Patrice Denefle, Nicolas Duverger, Jean-Charles Fruchart, Gérald Luc, Gérard Turpin, Gerd Assmann, Harald Funke
-
Patent number: 6248841Abstract: A novel process has been developed for the treatment of crosslinked ethylene-propylene diene monomer (EPDM) elastomer material to decrease its residual peroxide levels. EPDM is used to form the seats and neck gaskets of metering valves used in metered-dose inhalers (MDI). For filled and inverted MDI units these EPDM components are in direct contact with the pharmaceutical formulation media. The process involves exposing the EPDM valve components to a solution of 2-mercaptoethanol, a chemical reducing agent. The 2-mercaptoethanol greatly diminishes the residual peroxide levels in EPDM by reducing the peroxide functional groups to the corresponding hydroxyl groups. EPDM components treated in this manner have demonstrated very low peroxide levels and, consequently, greatly improved compatibility with the pharmaceutical formulation in the inhaler. An advantage of this approach is that the treated EPDM would likely retain its favorable physical properties and its good performance in metering valves.Type: GrantFiled: September 30, 1999Date of Patent: June 19, 2001Assignee: Aventis Pharmaceuticals Products Inc.Inventors: Karl M. Gelotte, Joseph D'Silva
-
Patent number: 6245760Abstract: This invention is directed to quinoline/quinoxaline compounds which inhibit platelet-derived growth factor or p56lck tyrosine kinase activity, to pharmaceutical compositions comprising these compounds, and to the use of these compounds for treating a patient suffering from or subject to disorders/conditions involving cellular differentiation, proliferation, extracellular matrix production or mediator release and/or T cell activation and proliferation.Type: GrantFiled: November 24, 1998Date of Patent: June 12, 2001Assignee: Aventis Pharmaceuticals Products, IncInventors: Wei He, Michael R. Myers, Alfred P. Spada
-
Patent number: 6235909Abstract: This invention is directed to methods for the preparation of [1S-[1a,2b,3b,4a(S*)]]-4-[7-[[-(3-chloro-2-thienyl)methyl]propyl]amino]-3 H-imidazo[4,5-b]pyridin-3-yl]]-N-ethyl-2,3-dihydroxycyclopentanecarboxamide, methods for the preparation of intermediates thereto, and to said intermediates themselves.Type: GrantFiled: July 28, 2000Date of Patent: May 22, 2001Assignee: Aventis Pharmaceuticals Products Inc.Inventors: Herve Garcia, Patrick Leon, Benoit J. Vanasse
-
Patent number: 6184382Abstract: The invention is directed to improved methods for preparing N6-substituted adenosine derivatives, to intermediates useful therefor and to methods of preparing these intermediates.Type: GrantFiled: January 12, 2000Date of Patent: February 6, 2001Assignee: Aventis Pharmaceuticals Products Inc.Inventors: Diane C. Salazar, Walter Rodriguez, James P. Sherbine, Rick G. Woodward, Adam W. Sledeski, Matthew R. Powers, Michael K. O'Brien
-
Patent number: 6180632Abstract: This invention is directed to quinoline/quinoxaline compounds which inhibit platelet-derived growth factor or p56lck tyrosine kinase activity, to pharmaceutical compositions comprising these compounds, and to the use of these compounds for treating a patient suffering from or subject to disorders/conditions involving cellular differentiation, proliferation, extracellular matrix production or mediator release and/or T cell activation and proliferation.Type: GrantFiled: November 24, 1998Date of Patent: January 30, 2001Assignee: Aventis Pharmaceuticals Products Inc.Inventors: Michael R. Myers, Wei He, Alfred P. Spada, Martin P. Maguire
-
Patent number: 6180759Abstract: This invention is directed to a process for preparing a pseudotetrapeptide of formula I or a salt or prodrug thereof wherein is optionally nitrogen protected azaheterocyclyl; is a single or double bond; q is 1-5; B is alkyl, cycloalkyl, cycloalkylalkyl, alkylcycloalkyl, alkylcycloalkylalkyl, aryl, aralkyl, alkylaryl, or alkylaralkyl; Q2 is H or a carboxylic acid protecting group; J is —H, alkyl, cycloalkyl, cycloalkylalkyl, alkylcycloalkyl, alkylcycloalkylalkyl, aryl, substituted aryl, aralkyl, substituted aralkyl; L is OR1, or NR1R2, where R1 and R2 are independently —H, alkyl, cycloalkyl, cycloalkylalkyl, alkylcycloalkyl, alkylcycloalkylalkyl, aryl, aralkyl, alkylaryl or alkylaralkyl; and p is 1 or 2 which comprises the coupling of two dipeptides or psuedopeptides.Type: GrantFiled: April 7, 2000Date of Patent: January 30, 2001Assignee: Aventis Pharmaceuticals Products Inc.Inventors: James J. Mencel, Robert Stammler, Christophe Daubie, Michel Lavigne, Benoit J. Vanasse, Robert C. Liu, Patrick Leon, Geoffrey A. D'Netto, Adam W. Sledeski
-
Patent number: 6159978Abstract: This invention is directed to quinoline/quinoxaline compounds which inhibit platelet-derived growth factor tyrosine kinase and/or Lck tyrosine kinase, to pharmaceutical compositions comprising these compounds, and to the use of these compounds for treating a patient suffering from or subject to disorders/conditions involving cellular differentiation, proliferation, extracellular matrix production or mediator release and/or T cell activation and proliferation.Type: GrantFiled: November 24, 1998Date of Patent: December 12, 2000Assignee: Aventis Pharmaceuticals Product, Inc.Inventors: Michael R. Myers, Alfred P. Spada, Paul E. Persons, Martin P. Maguire
-
Patent number: RE37850Abstract: Endothelial cell growth factor is achieved through the application of recombinant DNA technology to prepare cloning vehicles encoding the ECGF protein and procedures are disclosed for recovering ECGF protein essentially free of other proteins of human origin. The product is useful for, among other purposes, diagnostic applications and as potential in the treatment of damaged blood vessels or other endothelial cell-lined structures.Type: GrantFiled: March 28, 2000Date of Patent: September 17, 2002Assignee: Aventis Pharmaceuticals Products Inc.Inventors: Michael C. Jaye, Wilson Burgess, Thomas Maciag, William N. Drohan